Clinical Trials Logo

Filter by:
NCT ID: NCT00932451 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Start date: January 2010
Phase: Phase 2
Study type: Interventional

This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.

NCT ID: NCT00929539 Completed - Clinical trials for Type II Diabetes Mellitus

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Start date: June 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of JTT-130 on diabetes as well as the safety and tolerability of JTT-130 in obese Type 2 diabetic patients.

NCT ID: NCT00929110 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

GLOW2
Start date: June 2009
Phase: Phase 3
Study type: Interventional

This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.

NCT ID: NCT00928512 Completed - Clinical trials for Rheumatoid Arthritis

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

Start date: July 2009
Phase: Phase 2
Study type: Interventional

This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.

NCT ID: NCT00927810 Completed - Gouty Arthritis Clinical Trials

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Start date: June 5, 2009
Phase: Phase 2
Study type: Interventional

This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.

NCT ID: NCT00925600 Completed - Prostate Cancer Clinical Trials

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Start date: November 2009
Phase: Phase 3
Study type: Interventional

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation therapy.

NCT ID: NCT00925587 Completed - Anemia Clinical Trials

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Start date: June 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether once monthly (QM) dosing of darbepoetin alfa is non-inferior to that of once every 2 week (Q2W) dosing of darbepoetin alfa for the correction of anemia in patients with Chronic Kidney Disease who are not receiving dialysis.

NCT ID: NCT00923091 Completed - Clinical trials for Essential Hypertension

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Start date: June 2009
Phase: Phase 3
Study type: Interventional

This study is to determine the change in blood pressure from the administration of Olmesartan/Amlodipine/Hydrochlorothiazide triple combinations compared to dual combinations with Olmesartan/Amlodipine.

NCT ID: NCT00921752 Completed - Cardiovascular Risk Clinical Trials

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)

C2 -CORVUS
Start date: May 2009
Phase: N/A
Study type: Observational

To demonstrate a higher percent rate of achieved target lipid goals among patients at high cardiovascular risk using more potent lipid-lowering treatment options including high-potency statins and combination therapies.

NCT ID: NCT00916422 Completed - Clinical trials for Seasonal Allergic Rhinitis

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen

Start date: June 2008
Phase: Phase 3
Study type: Interventional

The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerised with glutaraldehyde)of the subcutaneous injection of Phleum pratense pollen in the treatment of patients affected by allergic rhinitis/ rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the Score regarding Symptoms and consumption of the medication.